ArticleThe Journal of investigative dermatology2010
Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma.
Article in The Journal of investigative dermatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Progress in COVID research and developments during pandemic.View (Beijing, China) · 2022Review
- Hydroxymethylation and tumors: can 5-hydroxymethylation be used as a marker for tumor diagnosis and treatment?Human genomics · 2020Review
- Review
- Expression of Estrogen Receptor Alpha in Malignant Melanoma.Advanced biomedical research · 2017Article
- 5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Article
- Germline determinants of clinical outcome of cutaneous melanoma.Pigment cell & melanoma research · 2016Review
- Review
- Stage-specific prognostic biomarkers in melanoma.Oncotarget · 2015Article
- Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles.BMC cancer · 2014Article
- Diagnostic and prognostic biomarkers in melanoma.The Journal of clinical and aesthetic dermatology · 2014Review
- Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients.Clinical & experimental metastasis · 2014Article
- Robust linear regression model of Ki-67 for mitotic rate in gastrointestinal stromal tumors.Oncology letters · 2014Article
- Established and Emerging Biomarkers in Cutaneous Malignant Melanoma.Healthcare (Basel, Switzerland) · 2014Review
- A nine-gene signature predicting clinical outcome in cutaneous melanoma.Journal of cancer research and clinical oncology · 2013Article
- Article
- Article
- Multiplex serum biomarker assessments: technical and biostatistical issues.Journal of translational medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Among individuals with localized (Stage I-II) melanoma, stratifying patients by a number of phenotypic variables (e.g., depth of invasion, ulceration) yields a wide range of 10-year melanoma-specific survival rates. With the possible exception of Ki-67, no molecular assessment is routinely used. However, there have been a tremendous number of studies assessing protein expression by immunohistochemistry toward the goal of better prediction of recurrence. In a previous systematic review, which required publication of multivariable prognostic models as a strict inclusion criterion, we identified 37 manuscripts that collectively reported on 62 proteins. Data for 324 proteins extracted from 418 manuscripts did not meet our inclusion criteria for that study, but are revisited here, emphasizing trends of protein expression across either melanocytic lesion progression or gradations of tumor thickness. These identified 101 additional proteins that stratify melanoma, organized according to the Hanahan and Weinberg functional capabilities of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.